{"nctId":"NCT02268214","briefTitle":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","startDateStruct":{"date":"2014-11-11","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":833,"armGroups":[{"label":"Arm A: Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Arm B: Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Arm C: Placebo for Dapagliflozin","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for dapagliflozin"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo for dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Type 1 Diabetes mellitus (T1DM)\n* Central laboratory C-peptide \\< 0.7 ng/ml (0.23 nmol/L)\n* Insulin use for at least 12 months per patient reported or medical records\n* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening\n* Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening\n* If on MDI insulin administration, subject must be on ≥ 3x injections per day\n* Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%\n* Body mass index (BMI) ≥ 18.5 kg/m2\n\nExclusion Criteria:\n\n* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity\n* Taking metformin and/or thiazolidinediones within 2 months prior to screening\n* Taking any antidiabetic medication (other than insulin), within 1 month prior to screening\n\n  \\- Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration\n* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening\n* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening\n* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening\n* History of Addison's disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c From Baseline at Week 24","description":"Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model\\[RMM\\]).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.0537"},{"groupId":"OG001","value":"-0.47","spread":"0.0538"},{"groupId":"OG002","value":"-0.03","spread":"0.0540"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24","description":"Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model\\[RMM\\])","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.74","spread":"1.4881"},{"groupId":"OG001","value":"-12.16","spread":"1.4326"},{"groupId":"OG002","value":"1.16","spread":"1.6593"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percent Change in Body Weight From Baseline at Week 24","description":"Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model\\[RMM\\])","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":"0.2330"},{"groupId":"OG001","value":"-3.67","spread":"0.2299"},{"groupId":"OG002","value":"0.05","spread":"0.2407"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24","description":"Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model\\[RMM\\])","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.28","spread":"1.8862"},{"groupId":"OG001","value":"-12.97","spread":"1.9231"},{"groupId":"OG002","value":"5.06","spread":"1.9320"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24","description":"Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model\\[RMM\\])","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.92","spread":"1.9915"},{"groupId":"OG001","value":"-16.55","spread":"2.0419"},{"groupId":"OG002","value":"2.38","spread":"2.0477"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24","description":"Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose \\> 70 and \\<= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model\\[RMM\\])","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":"0.8824"},{"groupId":"OG001","value":"8.52","spread":"0.9000"},{"groupId":"OG002","value":"-2.13","spread":"0.9032"}]}]}]},{"type":"SECONDARY","title":"Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events","description":"Subjects with HbA1c reduction from baseline to week 24 (LOCF) \\>= 0.5% and without severe hypoglycemia events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":277},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Urinary tract infection","Influenza","Headache"]}}}